Follow-up is managed internally in 94% of centers and is programmed according to international guidelines in 52% of high-volume hospitals (>25 melanoma diagnoses per year); the remainder use internal guidelines; fewer low-volume centers (≤25 diagnoses per year) have internal guidelines (25%, p = 0.001). Instrumental examinations for stage III and IV disease are similar, while the examination interval changes from 3/4 months for stage III to 2/3 months for stage IV, and use of PET/CT increases from 44 to 54%. Overall, thoracic and abdominal CT is used most for follow-up in stage III (83%), while bone scintigraphy is used more commonly in low-volume centers (41 vs. 19%, p = 0.003), despite similar use of PET/CT (48 vs. 41%). Brain CT or MRI is more common in high-volume centers (63 vs. 39%, p > 0.0001), as is echography of draining lymph nodes (71 vs. 52%, p = 0.01). Hepatic/abdominal echography and thoracic radiography are used in about 50% of centers, regardless of type. In stage IV, use of bone scintigraphy is similar among groups (ca. 40%); brain CT/NMR use increases from 51 to 64% and is more common in high-volume centers (p = 0.03). Lymph node echography is more common in high-volume centers (56 vs. 39%, p = 0.03).

Keywords:
Melanoma follow-up, Follow-up planning
1.
Johnson FE, Rosati G, Ambrosini G, Mandala M, Pinna N, Daniele B, Pavia G, Virgo KS, Longo WE, Grossmann EM, Fossati R: Colorectal cancer patient follow-up after surgery with curative intent. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(suppl):abstract 3695.
2.
Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR: Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 2007;33:665-680.
3.
Pirard D, Heenen M, Melot C, Vereecken P: Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 2004;208:43-48.
4.
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R: Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 2007;17:393-399.
5.
Brenner DJ, Hall EJ: Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007;357:2277-2284.
6.
Francken AB, Hoekstra HJ: Follow-up of melanoma patients: the need for evidence-based protocols. Ann Surg Oncol 2009;16:804-805.
7.
Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD, Ollila DW: Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 2009;16:941-947.
8.
Morton RL, Craig JC, Thompson JF: The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol 2009;16:571-577.
9.
McKenna DB, Marioni JC, Lee RJ, Prescott RJ, Doherty VR: A comparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma. Br J Dermatol 2004;151:636-644.
10.
Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B, Meier F, Schittek B, Blaheta HJ, Blum A, Rassner G: Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003;21:520-529.
11.
Francken AB, Bastiaannet E, Hoekstra HJ: Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005;6:608-621.
12.
Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC: Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999;86:2252-2258.
13.
Tsao H, Feldman M, Fullerton JE, Sober AJ, Rosenthal D, Goggins W: Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 2004;140:67-70.
14.
Egberts F, Hitschler WN, Weichenthal M, Hauschild A: Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res 2009;19:31-35.
15.
Bastiaannet E, Hoekstra-Weebers JE, Francken AB, Jager PL, van der Jagt EJ, Hoekstra HJ: Perception of burden experienced during diagnostic tests by melanoma patients with lymph node metastases. Melanoma Res 2009;19:36-41.
16.
Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG: Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 1997;80:1052-1064.
17.
Amersi FF, Terando AM, Goto Y, Scolyer RA, Thompson JF, Tran AN, Faries MB, Morton DL, Hoon DS: Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res 2008;14:638-645.
18.
Dummer R, Panizzon R, Bloch PH, Burg G; Task Force ‘Skin Cancer': Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005;210:39-44.
19.
Dummer R, Hauschild A, Jost L; ESMO Guidelines Working Group: Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(suppl 2):ii86-ii88.
20.
Tanaka R, Koyanagi K, Narita N, Kuo C, Hoon DS: Prognostic molecular biomarkers for cutaneous malignant melanoma. J Surg Oncol 2011;104:438-446.
21.
Leiter U, Buettner PG, Eigentler TK, Forschner A, Meier F, Garbe C: Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res 2010;20:240-246.
22.
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R: Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res 2008;18:61-67.
23.
Bassères N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, Collet-Vilette AM, Lota I, Bonerandi JJ: Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995;191:199-203.
24.
Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D: Primary staging and follow-up in melanoma patients - monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002;87:151-157.
25.
Bauer J, Blum A, Strohhäcker U, Garbe C: Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy. Br J Dermatol 2005;152:87-92.
26.
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R: Brief guidelines: malignant melanoma of the skin (in German). J Dtsch Dermatol Ges 2006;4:344-349.
27.
Leiter U, Marghoob AA, Lasithiotakis K, Eigentler TK, Meier F, Meisner C, Garbe C: Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Res 2009;19:50-57.
28.
Leiter U, Eigentler TK, Forschner A, Pflugfelder A, Weide B, Held L, Meier F, Garbe C: Excision guidelines and follow-up strategies in cutaneous melanoma: facts and controversies. Clin Dermatol 2010;28:311-315.
29.
Mingozzi E, Fregosi S, Gandini S, Stanganelli I, Chiarion-Sileni V, Testori A: Melanoma Task Force (META) project in Italy: methodology. Dermatology 2013;226(suppl 1): 1-2.
30.
Yancovitz M, Finelt N, Warycha MA, Christos PJ, Mazumdar M, Shapiro RL, Pavlick AC, Osman I, Polsky D, Berman RS: Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007;110:1107-1114.
31.
Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, de Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ: Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009;27:4774-4780.
32.
Chao C, Wong SL, Ross MI, Reintgen DS, Noyes RD, Cerrito PB, Edwards MJ, McMasters KM; Sunbelt Melanoma Trial Group: Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002;184:520-524.
33.
Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN: Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011;103:129-142.
34.
Devine D, Parker PA, Fouladi RT, Cohen L: The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 2003;12:453-462.
35.
Rudy RR, Rosenfeld LB, Galassi JP, Parker J, Schanberg R: Participants' perceptions of a peer-helper, telephone-based social support intervention for melanoma patients. Health Commun 2001;13:285-305.
36.
Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG: Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 2008;15:2206-2214.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.